FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
BofA Securities analyst Jason Gerberry raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $63.00 (from $60.00) while maintaining a Buy rating.
The analyst comments "Tarsus reported strong 1Q results with sales of Xdemvy (demodex blepharitis) meaningfully outperforming expectations ($25m vs. $17m cons).... More

